Cargando…

Quantifying competitive advantages of mutant strains in a population involving importation and mass vaccination rollout

The SARS-CoV-2 Delta variant, known as B.1.617.2 and first identified in India, is becoming a dominant strain in many countries due to its extreme infectiousness. Assessing and quantifying the transmissibility and competitive advantage of the Delta variant is of major significance for countries arou...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Fan, Yang, Xinpei, Cheke, Robert A., Xiao, Yanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349563/
https://www.ncbi.nlm.nih.gov/pubmed/34395957
http://dx.doi.org/10.1016/j.idm.2021.08.001
_version_ 1783735588630822912
author Xia, Fan
Yang, Xinpei
Cheke, Robert A.
Xiao, Yanni
author_facet Xia, Fan
Yang, Xinpei
Cheke, Robert A.
Xiao, Yanni
author_sort Xia, Fan
collection PubMed
description The SARS-CoV-2 Delta variant, known as B.1.617.2 and first identified in India, is becoming a dominant strain in many countries due to its extreme infectiousness. Assessing and quantifying the transmissibility and competitive advantage of the Delta variant is of major significance for countries around the world so that appropriate measures to mitigate and even eliminate the epidemic can be introduced. Aiming at such problems, we proposed a method to model the invasion process of a novel strain and estimate the competitive advantage of the invading strain over the local strain. We applied this method to study the invasion and spread of the Delta variant into England. We have estimated the basic reproduction number of the Delta variant as being 49% higher than that of the Alpha variant (CI: 45–52%), assuming a mean generation interval of 5 days with a standard deviation of 3 days. In the period 11 April to 17 May 2021, the effective reproduction number of the Delta variant was 65% higher than that of the Alpha variant in England (CI: 61–70%). Our results show that the Delta variant has a significantly higher transmission capacity than other strains, which explains the rebound of the epidemic in many countries, even in those with relatively high vaccination coverages.
format Online
Article
Text
id pubmed-8349563
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-83495632021-08-09 Quantifying competitive advantages of mutant strains in a population involving importation and mass vaccination rollout Xia, Fan Yang, Xinpei Cheke, Robert A. Xiao, Yanni Infect Dis Model Original Research Article The SARS-CoV-2 Delta variant, known as B.1.617.2 and first identified in India, is becoming a dominant strain in many countries due to its extreme infectiousness. Assessing and quantifying the transmissibility and competitive advantage of the Delta variant is of major significance for countries around the world so that appropriate measures to mitigate and even eliminate the epidemic can be introduced. Aiming at such problems, we proposed a method to model the invasion process of a novel strain and estimate the competitive advantage of the invading strain over the local strain. We applied this method to study the invasion and spread of the Delta variant into England. We have estimated the basic reproduction number of the Delta variant as being 49% higher than that of the Alpha variant (CI: 45–52%), assuming a mean generation interval of 5 days with a standard deviation of 3 days. In the period 11 April to 17 May 2021, the effective reproduction number of the Delta variant was 65% higher than that of the Alpha variant in England (CI: 61–70%). Our results show that the Delta variant has a significantly higher transmission capacity than other strains, which explains the rebound of the epidemic in many countries, even in those with relatively high vaccination coverages. KeAi Publishing 2021-08-08 /pmc/articles/PMC8349563/ /pubmed/34395957 http://dx.doi.org/10.1016/j.idm.2021.08.001 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Xia, Fan
Yang, Xinpei
Cheke, Robert A.
Xiao, Yanni
Quantifying competitive advantages of mutant strains in a population involving importation and mass vaccination rollout
title Quantifying competitive advantages of mutant strains in a population involving importation and mass vaccination rollout
title_full Quantifying competitive advantages of mutant strains in a population involving importation and mass vaccination rollout
title_fullStr Quantifying competitive advantages of mutant strains in a population involving importation and mass vaccination rollout
title_full_unstemmed Quantifying competitive advantages of mutant strains in a population involving importation and mass vaccination rollout
title_short Quantifying competitive advantages of mutant strains in a population involving importation and mass vaccination rollout
title_sort quantifying competitive advantages of mutant strains in a population involving importation and mass vaccination rollout
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349563/
https://www.ncbi.nlm.nih.gov/pubmed/34395957
http://dx.doi.org/10.1016/j.idm.2021.08.001
work_keys_str_mv AT xiafan quantifyingcompetitiveadvantagesofmutantstrainsinapopulationinvolvingimportationandmassvaccinationrollout
AT yangxinpei quantifyingcompetitiveadvantagesofmutantstrainsinapopulationinvolvingimportationandmassvaccinationrollout
AT chekeroberta quantifyingcompetitiveadvantagesofmutantstrainsinapopulationinvolvingimportationandmassvaccinationrollout
AT xiaoyanni quantifyingcompetitiveadvantagesofmutantstrainsinapopulationinvolvingimportationandmassvaccinationrollout